These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9378511)

  • 21. Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: an in vivo fast-cyclic voltammetry study.
    Xi ZX; Fuller SA; Stein EA
    J Pharmacol Exp Ther; 1998 Jan; 284(1):151-61. PubMed ID: 9435173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of kappa-opioid receptors and sigma receptors in memory function demonstrated using an antisense strategy.
    Hiramatsu M; Hoshino T
    Brain Res; 2004 Dec; 1030(2):247-55. PubMed ID: 15571673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ethosuximide on dopaminergically mediated behaviours.
    Jadhav JH; Balsara JJ; Jeurkar AJ; Chandorkar AG
    Indian J Physiol Pharmacol; 1981; 25(3):274-8. PubMed ID: 7197666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.
    Vanderah TW; Schteingart CD; Trojnar J; Junien JL; Lai J; Riviere PJ
    J Pharmacol Exp Ther; 2004 Jul; 310(1):326-33. PubMed ID: 14993260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G; Rogóz Z; Wieczorek A
    Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of L-histidine and chlorcyclizine on apomorphine-induced climbing behaviour and methamphetamine stereotypy in mice.
    Joshi VV; Balsara JJ; Jadhav JH; Chandorkar AG
    Eur J Pharmacol; 1981 Feb; 69(4):499-502. PubMed ID: 6113966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
    Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
    Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral synergism between D(1) and D(2) dopamine receptors in mice does not depend on gap junctions.
    Nolan EB; Harrison LM; Lahoste GJ; Ruskin DN
    Synapse; 2007 May; 61(5):279-87. PubMed ID: 17318881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of histaminergic mechanisms in the cataleptogenic effect of morphine in mice.
    Muley MP; Balsara JJ; Jadhav JH; Chandorkar AG
    J Pharm Pharmacol; 1982 Jan; 34(1):34-7. PubMed ID: 6121029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of metoclopramide pretreatment on apomorphine induced cage climbing behaviour.
    Uppal RP
    Indian J Exp Biol; 1984 Apr; 22(4):224-5. PubMed ID: 6541194
    [No Abstract]   [Full Text] [Related]  

  • 33. Dopaminergic involvement in the mechanism of action of pentazocine.
    Hernández LL; Appel JB
    Behav Neural Biol; 1979 Aug; 26(4):384-400. PubMed ID: 227353
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of acute topical application of +-pentazocine on the mechanical allodynia in diabetic mice.
    Ohsawa M; Hayashi SS; Kamei J
    Eur J Pharmacol; 2010 Sep; 641(1):49-53. PubMed ID: 20546721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Narcotic analgesics and stereotyped behaviour in mice.
    Langwiński R; Niedzielski J
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Jul; 312(3):225-7. PubMed ID: 6105624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitization to the behavioral effects of cocaine: modulation by dynorphin and kappa-opioid receptor agonists.
    Shippenberg TS; Rea W
    Pharmacol Biochem Behav; 1997 Jul; 57(3):449-55. PubMed ID: 9218269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naloxone blockade of (-)pentazocine-induced changes in auditory function.
    Sahley TL; Musiek FE; Nodar RH
    Ear Hear; 1996 Aug; 17(4):341-53. PubMed ID: 8862972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gender difference in analgesic response to the kappa-opioid pentazocine.
    Gear RW; Gordon NC; Heller PH; Paul S; Miaskowski C; Levine JD
    Neurosci Lett; 1996 Mar; 205(3):207-9. PubMed ID: 8852594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockade of opioid-induced changes in auditory function at the level of the cochlea.
    Sahley TL; Nodar RH; Musiek FE
    Ear Hear; 1996 Dec; 17(6):552-8. PubMed ID: 8979043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent developments in the pharmacology and clinical use of pentazocine].
    Sugai N
    Masui; 1991 Jul; 40(7):1037-41. PubMed ID: 1920775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.